At Fifteen Months Post-Launch, AbbVie’s Qulipta Outperforms Pfizer’s Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights

Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on par. EXTON, Pa., March 16, 2023 /PRNewswire/ — Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep…